PLCG2 and head and neck squamous cell carcinoma: CCL5 was found, in combination with FGF2, phospholipase C (PLCg2), frizzled receptor-4 (FZD4), and chemokine [C-X3-C motif] (CX3CL1), to be overexpressed in bevacizumab-resistant HNSCC [44].